The Omnipod 5 Aims to "Help Simplify Life with Diabetes"
Niko Pajkovic — January 28, 2022 — Lifestyle
References: omnipod & businesswire
Insulet Corporation, a leading manufacturer of tubeless insulin pump technology, has officially received FDA clearance for its newest Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) -- the first tubeless automated insulin delivery (AID) device that is compatible with Dexcom G6 and smartphone devices.
More specifically, the Omnipod 5 was developed for individuals with type 1 diabetes who are aged six and up. In addition, the company says that the device was designed to "help simplify life with diabetes" by removing the need for tubes, fingersticks, and multiple daily injections.
“We are incredibly proud of this simple-to-use, elegant system, designed to deliver unmatched freedom and to greatly simplify insulin management and improve glucose control for our users," said Shacey Petrovic, President and Chief Executive Officer of Insulet.
Image Credit: Insulet Corporation
More specifically, the Omnipod 5 was developed for individuals with type 1 diabetes who are aged six and up. In addition, the company says that the device was designed to "help simplify life with diabetes" by removing the need for tubes, fingersticks, and multiple daily injections.
“We are incredibly proud of this simple-to-use, elegant system, designed to deliver unmatched freedom and to greatly simplify insulin management and improve glucose control for our users," said Shacey Petrovic, President and Chief Executive Officer of Insulet.
Image Credit: Insulet Corporation
Trend Themes
1. Automated Insulin Delivery Systems - With the creation of the Omnipod 5, the first tubeless and smartphone-compatible insulin delivery system has emerged, offering individuals with diabetes unparalleled freedom, ease, and glucose control.
2. Connected Medical Devices - As more medical devices shift towards wireless, smartphone-compatibility and cloud connectivity, there is a disruption opportunity to create specialized, connected medical devices within the healthcare industry.
3. Non-invasive Medical Devices - By removing the need for tubes, fingersticks, and daily injections with tubeless insulin delivery systems, there is potential for the development of even more non-invasive medical devices and medical procedures.
Industry Implications
1. Medical Devices - Insulet Corporation's Omnipod 5 paves the way for more disruptive innovations in the medical device industry, particularly in the area of automated insulin delivery systems.
2. Healthcare - As more health applications are developed to work with smartphones, there is a new disruption opportunity to create specialized apps centered around non-invasive medical device usage and automated insulin delivery.
3. Technology - The Omnipod 5 proves the potential for integrating technology, wireless, and cloud-based connectivity in healthcare and medical device industries to disrupt the traditional procedures and methods of insulin delivery and diabetes management.
2
Score
Popularity
Activity
Freshness
